Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | WRN | Q14191 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19735284 | 0.87 | APP (0.48) | KIF11NPC1RAB9AKDM4ETSHR | |
| SCHEMBL13197642 | 0.85 | TSHR (0.46) | KIF11NPC1RAB9AKDM4ETSHR | |
| SCHEMBL9927249 | 0.84 | APP (0.48) | NPC1RAB9AKDM4EPGRALDH1A1 | |
| SCHEMBL16546586 | 0.84 | PGR (0.41) | NPC1RAB9AKDM4EPGRALDH1A1 | |
| SCHEMBL13197653 | 0.84 | TSHR (0.44) | KIF11NPC1RAB9AKDM4ETSHR | |
| SCHEMBL13197643 | 0.83 | TSHR (0.43) | KIF11NPC1RAB9AKDM4ETSHR | |
| SCHEMBL12622623 | 0.82 | KIF11 (0.53) | KIF11PGRALDH1A1 | |
| SCHEMBL10300218 | 0.82 | APP (0.46) | NPC1RAB9AKDM4EPGRALDH1A1 | |
| SCHEMBL13424304 | 0.82 | APP (0.46) | NPC1RAB9AKDM4EPGRALDH1A1 | |
| SCHEMBL13197616 | 0.82 | TSHR (0.42) | KIF11NPC1RAB9AKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791104-B2 | 1,4-benzodiazepine-2,5-diones with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-10-03 | — | — | US | disclosed |
| US-20120088757-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088757-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-12 | — | — | US | disclosed |
| US-8088759-B2 | 1,4-benzodiazepine-2,5-diones with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-01-03 | — | — | US | disclosed |
| US-7947684-B2 | anticoagulants; immunomoderators; antiinflammatory agents | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-05 | — | — | US | disclosed |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | BAD, GABRA5, GABRB1 | KIF11 4574/4885NPC1 2603/4885RAB9A 3739/4885 |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | ATP5F1A, ATP5MF, MT-ATP6 | KIF11 3565/4885NPC1 1087/4885RAB9A 2138/4885 |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | BAD, GABRA5, GABRB1 | KIF11 4574/4885NPC1 2603/4885RAB9A 3739/4885 |
| US-20120088757-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | BAD, GABRA5, GABRB1 | KIF11 4574/4885NPC1 2603/4885RAB9A 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.